Dual HER2 Blockade Versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Journal of Oncology - United States
doi 10.1155/2020/5169278
Full Text
Open PDFAbstract
Available in full text
Categories
Date
March 16, 2020
Authors
Publisher
Hindawi Limited